Nir Sassi, Chief Financial Officer of Nasus Pharma Ltd, filed a Form 3 initial statement of beneficial ownership on November 19, 2026, disclosing share options to purchase 115,000 ordinary shares granted on November 11, 2026.
Key Highlights
- Reporting person: Nir Sassi, identified in the filing as Chief Financial Officer of Nasus Pharma Ltd (NSRX).
- Grant date: Options to purchase 115,000 ordinary shares, no par value, were granted on November 11, 2026, under the company's 2019 Incentive Option Plan.
- Three tranches: 38,333 options at an exercise price of $3.50, 38,333 options at $4.00, and 38,334 options at $5.00, all expiring November 11, 2036.
- Vesting schedule: One-third vests on November 11, 2027; the remaining two-thirds vest in eight equal quarterly installments beginning February 11, 2028.
- No non-derivative holdings reported: Table I of the filing lists no directly or indirectly owned non-derivative securities.
- All ownership is direct: Each option tranche is listed as directly held (Form ownership code "D").
Nasus Pharma CFO's Initial Beneficial Ownership Filing Details Option Grant Terms
According to the Form 3 filed with the U.S. Securities and Exchange Commission on November 19, 2026, Nir Sassi submitted an initial statement of beneficial ownership in connection with his role as Chief Financial Officer of Nasus Pharma Ltd, traded under the ticker NSRX. The event requiring the statement was dated November 11, 2026, the same date the options were granted.
The filing discloses three tranches of derivative securities, all classified as "Share options (right to buy)" under the company's 2019 Incentive Option Plan. The first tranche covers 38,333 ordinary shares at an exercise price of $3.50, exercisable beginning November 11, 2027. The second tranche covers 38,333 ordinary shares at $4.00 per share, and the third covers 38,334 ordinary shares at $5.00 per share; both of the latter tranches become exercisable beginning February 11, 2028. All three tranches carry an expiration date of November 11, 2036, according to the filing.
The filing's explanation of responses states: "The options vest over thirty-six (36) months: one-third on November 11, 2027, and the remaining two-thirds in eight equal quarterly installments beginning February 11, 2028. Any fractional shares resulting from vesting will be deferred to the next vesting tranche on a rolling basis." The filing was signed by Nir Sassi and dated November 19, 2026. No non-derivative securities were reported as beneficially owned.
What Was Disclosed
Nasus Pharma Ltd CFO Nir Sassi filed an initial Form 3 disclosing options to purchase 115,000 ordinary shares in three tranches at exercise prices of $3.50, $4.00, and $5.00, granted November 11, 2026, under the company's 2019 Incentive Option Plan, all held directly.




Please wait processing your request...